MedTrace Logo

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

NCT05781750 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-12-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).

Conditions

Interventions

DRUG

zetomipzomib

Subcutaneous injection of zetomipzomib

DRUG

placebo

Subcutaneous injection of placebo

Sponsors & Collaborators

  • Kezar Life Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Kezar · Kezar Life Sciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-03
Primary Completion
2024-11-08
Completion
2024-11-08
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • China
  • Colombia
  • Greece
  • Guatemala
  • India
  • Malaysia
  • Philippines
  • South Africa
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05781750 on ClinicalTrials.gov